Log in

Relevant bibliographies by topics / Comorbidité – Cancer / Journal articles

To see the other types of publications on this topic, follow the link: Comorbidité – Cancer.

Journal articles on the topic 'Comorbidité – Cancer'

Author: Grafiati

Published: 11 January 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Comorbidité – Cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kaikani, W., and P. Bachmann. "Conséquences d'une comorbidité trop souvent négligée en cancérologie: la dénutrition." Bulletin du Cancer 96, no. 6 (2009): 659–64. http://dx.doi.org/10.1684/bdc.2009.0875.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Saba, G. "Comorbidités somatiques et résistance thérapeutique." European Psychiatry 29, S3 (2014): 664. http://dx.doi.org/10.1016/j.eurpsy.2014.09.053.

Full text

Abstract:

RésuméParmi les facteurs de résistance thérapeutique d’un épisode dépressif majeur (EDM), on peut évoquer d’emblée l’association aux pathologies somatiques, au premier rang desquelles figurent les affections endocriniennes, cardiovasculaires et métaboliques. Plusieurs d’entre elles sont d’ailleurs susceptibles d’engendrer la survenue d’un EDM, en pérenniser les manifestations cliniques, et conduire à la résistance aux traitements classiquement proposés dans cette indication. La co-occurrence d’une pathologie somatique et d’un EDM n’est pas une situation rare en pratique clinique quotidienne da

APA, Harvard, Vancouver, ISO, and other styles

3

Blel, S., S. Joobeur, H. Mribah, et al. "Valeur pronostique du score de comorbidité simplifié dans le cancer bronchique non à petites cellules métastatique." Revue des Maladies Respiratoires 34 (January 2017): A198—A199. http://dx.doi.org/10.1016/j.rmr.2016.10.467.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Iecovich, Esther, and Aya Biderman. "Concordance between Self-Reported and Physician-Reported Chronic Co-morbidity among Disabled Older Adults." Canadian Journal on Aging / La Revue canadienne du vieillissement 32, no. 3 (2013): 287–97. http://dx.doi.org/10.1017/s0714980813000366.

Full text

Abstract:

RÉSUMÉLa discordance entre les auto-rapports et les dossiers médicaux reflètent des éléments concernant les patients et les prestataires qui ont des implications pour la recherche et la gestion. Cette étude a examiné la discordance et les facteurs socio-démographiques qui expliquent la concordance. Un échantillon téléologique de 402 personnes âgées handicapées a été interrogés à l’aide d’un questionnaire structuré. On a trouvé les concordances les plus hauts pour le diabète, l’accident cardiovasculaire (CVA), et le cancer, et les plus bas pour l’arthrite, et les conditions rénales et digestive

APA, Harvard, Vancouver, ISO, and other styles

5

Stewart, Andrew J., Scott B. Patten, Kirsten M. Fiest, Tyler S. Williamson, James P. Wick, and Paul E. Ronksley. "Facteurs associés aux dépenses élevées en soins de santé chez les patients atteints de schizophrénie." Promotion de la santé et prévention des maladies chroniques au Canada 42, no. 10 (2022): 486–95. http://dx.doi.org/10.24095/hpcdp.42.10.02f.

Full text

Abstract:

Introduction La compréhension des motifs de la grande variation des dépenses en soins de santé chez les patients atteints de schizophrénie est susceptible de contribuer à l’élaboration d’interventions visant à améliorer les résultats pour les patients et l’efficience des dépenses en soins de santé. Notre étude visait à déterminer les facteurs associés aux dépenses élevées en soins de santé chez les patients atteints de schizophrénie. Méthodologie Cette étude transversale en série a utilisé les dossiers de santé administratifs de résidents de l’Alberta (Canada) entre le 1er janvier 2008 et le 3

APA, Harvard, Vancouver, ISO, and other styles

6

Othmane, M. "Évaluation d’une ablation isotopique en ambulatoire à faible dose (minidose) chez des patients ayant un cancer thyroïdien différencié et une comorbidité sévère." Annales d'Endocrinologie 77, no. 4 (2016): 303. http://dx.doi.org/10.1016/j.ando.2016.07.171.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Chen, Yang, and Rong Xu. "Mining Cancer-Specific Disease Comorbidities from a Large Observational Health Database." Cancer Informatics 13s1 (January 2014): CIN.S13893. http://dx.doi.org/10.4137/cin.s13893.

Full text

Abstract:

Cancer comorbidities often reflect the complex pathogenesis of cancers and provide valuable clues to discover the underlying genetic mechanisms of cancers. In this study, we systematically mine and analyze cancer-specific comorbidity from the FDA Adverse Event Reporting System. We stratified 3,354,043 patients based on age and gender, and developed a network-based approach to extract comorbidity patterns from each patient group. We compared the comorbidity patterns among different patient groups and investigated the effect of age and gender on cancer comorbidity patterns. The results demonstra

APA, Harvard, Vancouver, ISO, and other styles

8

Justiniano, Carla Francesca, Zhaomin Xu, Adan Z. Becerra, et al. "Comorbidity and cause of death after surgery for early stage colorectal cancer (CRC)." Journal of Clinical Oncology 35, no. 15_suppl (2017): e15139-e15139. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e15139.

Full text

Abstract:

e15139 Background: Early stage (I/II) CRC is traditionally associated with relatively good prognosis at 90% relative survival. The probability of non-cancer death in CRC patients is associated with comorbidity burden; however, there is paucity of data evaluating this association in colon versus rectal cancer. This study examines the impact of comorbdity on 5-year mortality and cause of death after resection for early stage CRC. Methods: Linked patient-level data from the New York State Cancer Registry & Statewide Planning and Research Cooperative System was queried for 2004-2013 patients w

APA, Harvard, Vancouver, ISO, and other styles

9

Read, William L., Ryan M. Tierney, Nathan C. Page, et al. "Differential Prognostic Impact of Comorbidity." Journal of Clinical Oncology 22, no. 15 (2004): 3099–103. http://dx.doi.org/10.1200/jco.2004.08.040.

Full text

Abstract:

Purpose Cancer patients with concurrent comorbid conditions have worse outcomes than patients with no comorbidities. We hypothesized that the prognostic impact of comorbidities would be greatest for patients with cancers associated with a long natural history and least in patients with aggressive cancers. Patients and Methods Using the Barnes-Jewish Hospital Oncology Data Services cancer registry, we grouped 11,558 patients with breast, lung, colon, or prostate cancer by morphologic stage at diagnosis and then determined the 1-year overall survival rate for each group. Overall, severity of com

APA, Harvard, Vancouver, ISO, and other styles

10

Salas, Maribel, Mackenzie Henderson, Meera Sundararajan, et al. "Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review." PLOS ONE 16, no. 6 (2021): e0252925. http://dx.doi.org/10.1371/journal.pone.0252925.

Full text

Abstract:

Objective To identify comorbidity indices that have been validated in cancer populations, with a focus on breast cancer and human epidermal growth factor receptor-2-positive (HER2+) breast cancer. Study design and setting A systematic review of the literature on the use of comorbidity indices in any cancer, breast cancer, and HER2+ breast cancer using Ovid and PubMed. Results The final data set comprised 252 articles (252 any cancer, 39 breast cancer, 7 HER2+ breast cancer). The most common cancers assessed were hematologic and breast, and the most common comorbidity index used was the Charlso

APA, Harvard, Vancouver, ISO, and other styles

11

Jalenques, I., C. Lemogne, A. Consoli, and E. Haffen. "SMP – Diagnostic et traitement personnalisés des dépressions : enjeux et perspectives d’avenir." European Psychiatry 30, S2 (2015): S81. http://dx.doi.org/10.1016/j.eurpsy.2015.09.362.

Full text

Abstract:

La dépression unipolaire chez l’adulte est une maladie hétérogène, en raison de la multiplicité des causes et des mécanismes physiopathologiques vraisemblablement impliqués. La résistance thérapeutique est sans doute liée au défaut de mise en évidence de sous-groupes distincts qui nécessiteraient une prise en charge spécifique. Un diagnostic et un programme thérapeutique optimisés pour chaque patient constituent donc un enjeu majeur. La dépression entretient des relations réciproques avec les pathologies somatiques qui peuvent induire des états dépressifs par des mécanismes directs en raison d

APA, Harvard, Vancouver, ISO, and other styles

12

Lavery, Jessica A., Paul C. Boutros, Chaya S. Moskowitz, and Lee W. Jones. "Comorbidity in Midlife and Cancer Outcomes." JAMA Network Open 8, no. 4 (2025): e253469. https://doi.org/10.1001/jamanetworkopen.2025.3469.

Full text

Abstract:

ImportanceComorbidities in midlife are common but how these conditions are associated with cancer outcomes is poorly understood.ObjectiveTo investigate the association between different comorbidities and risk of incident cancer and cancer mortality.Design, Setting, and ParticipantsThis cohort study is a secondary analysis of the prospective Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial conducted at 10 PLCO screening centers across the US. Participants included adults aged 55 to 74 years without a history of cancer enrolled between 1993 and 2001. Statistical analysis was perfor

APA, Harvard, Vancouver, ISO, and other styles

13

D'Angelo, Christopher Robert, Brianna Novitsky, Sang Mee Lee, et al. "Comorbidity from Solid Tumor or Hematologic Malignancy Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) May Both Increase Non-Relapse Mortality." Blood 128, no. 22 (2016): 5844. http://dx.doi.org/10.1182/blood.v128.22.5844.5844.

Full text

Abstract:

Abstract Introduction Comorbidity prior to HCT predisposes to non-relapse mortality (NRM) and has been well described using the hematopoietic cell transplantation-comorbidity index (HCT-CI). Prior solid tumor automatically categorizes patients as high comorbidity whereas hematologic cancer different from the primary transplant indication is not scored (e.g., prior lymphoma in a patient with AML). No studies have explicitly characterized the risk from cancer comorbidity alone prior to HCT. Methods We retrospectively reviewed records of HCT patients 18 years and older who underwent first allogen

APA, Harvard, Vancouver, ISO, and other styles

14

Tabarés-Seisdedos, Rafael, and Jose M. Valderas. "Inverse comorbidity: the power of paradox in the advancement of science." Journal of Comorbidity 3, no. 1 (2013): 1–3. https://doi.org/10.15256/joc.2013.3.19.

Full text

Abstract:

<strong>Abstract: </strong>Research on comorbidity and multimorbidity is finally receiving the attention it deserves, particularly considering the magnitude and impact they have on health and the delivery of healthcare [1,2]. Numerous studies have demonstrated that individuals with Down’s syndrome, Parkinson’s disease, schizophrenia, diabetes, anorexia nervosa, Alzheimer’s disease, allergy related diseases, multiple sclerosis or Huntington’s disease (among other health problems) are protected against many forms of cancer, including solid tumors, smoking-related tum

APA, Harvard, Vancouver, ISO, and other styles

15

Gupta, S. "Cancer Survivors in Delaware: Impact of Comorbidity." European Psychiatry 67, S1 (2024): S367. http://dx.doi.org/10.1192/j.eurpsy.2024.754.

Full text

Abstract:

IntroductionDelaware’s recent longevity and aging trends predict a continual increase in the number of cancer survivors. As the cancer survivors live longer and age, the prevalence of comorbid chronic conditions tends to increase. Dual burden of cancer and comorbid chronic conditions can have significant and wide-ranging ramifications for cancer survivors. Comorbidity potentially affects the development, stage at diagnosis, treatment options, recurrence and long-term survival of people with cancer. Detailed delineation of Delaware adult cancer survivors including an exploration of comorbidity

APA, Harvard, Vancouver, ISO, and other styles

16

Haass, Nikolas K., Najah Nassif, and Eileen M. McGowan. "Switching the Sphingolipid Rheostat in the Treatment of Diabetes and Cancer Comorbidity from a Problem to an Advantage." BioMed Research International 2015 (2015): 1–9. http://dx.doi.org/10.1155/2015/165105.

Full text

Abstract:

Cancer and diabetes are among the most common diseases in western societies. Epidemiological studies have shown that diabetic patients have a significantly higher risk of developing a number of different types of cancers and that individuals with comorbidity (cancer and diabetes/prediabetes) have a poorer prognosis relative to nondiabetic cancer patients. The increasing frequency of comorbidity of cancer and diabetes mellitus, mainly type 2 diabetes, has driven the development of therapeutic interventions that target both disease states. There is strong evidence to suggest that balancing the s

APA, Harvard, Vancouver, ISO, and other styles

17

Ogle, Karen S., G. Marie Swanson, Nancy Woods, and Faouzi Azzouz. "Cancer and comorbidity." Cancer 88, no. 3 (2000): 653–63. http://dx.doi.org/10.1002/(sici)1097-0142(20000201)88:3<653::aid-cncr24>3.0.co;2-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Jerkovic Gulin, Sandra, Filippa Lundin, Olle Eriksson, and Oliver Seifert. "Lichen Sclerosus—Incidence and Comorbidity: A Nationwide Swedish Register Study." Journal of Clinical Medicine 13, no. 10 (2024): 2761. http://dx.doi.org/10.3390/jcm13102761.

Full text

Abstract:

Background: Data on the incidence and comorbidity of Lichen sclerosus (LS), based on validated nationwide population-based registries, remains scarce. Objective: To explore the incidence and association of comorbidities with LS in Sweden, emphasizing its potential links to malignancies and autoimmune disorders. Methods: A population-based retrospective open cohort study was conducted using the National Patient Register to identify all individuals diagnosed with LS (ICD-10 code L90.0) from 1 January 2001 to 1 January 2021. The study included 154,424 LS patients and a sex and age matched control

APA, Harvard, Vancouver, ISO, and other styles

19

Lam, Chun Sing, Rong Hua, Herbert H. Loong, Chun-Kit Ngan, and Yin Ting Cheung. "Association between comorbidity clusters and mortality in patients with cancer: A machine learning analysis of data from the US National Health and Nutrition Examination Survey 1999–2018." Journal of Clinical Oncology 42, no. 16_suppl (2024): 11132. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.11132.

Full text

Abstract:

11132 Background: Multimorbidity is common among patients with cancer; however, research on cancer prognosis has predominantly focused on cancers in isolation. This study identified comorbidity clusters among patients with cancer using machine learning and examine their associations with survival outcomes in a nationally representative sample of the US. Methods: This study used 10 survey cycles of the National Health and Nutrition Examination Survey from 1999 to 2018. Participants aged ≥20 years with a self-reported history of cancer were included. Comorbidities were ascertained through self-r

APA, Harvard, Vancouver, ISO, and other styles

20

Polednik, Katherine M., Aleksandr R. Bukatko, Matthew Gaubatz, et al. "Cumulative odds of increased comorbid score in head and neck cancer." Journal of Clinical Oncology 37, no. 15_suppl (2019): e17555-e17555. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e17555.

Full text

Abstract:

e17555 Background: Survival of head and neck cancer is impacted by known clinical factors, including anatomic subsite, stage of presentation, and treatment modality. An important clinical factor less explored is comorbidity burden. While it is known that a greater comorbidity burden is prognostic for poorer outcomes, it is unclear how the odds of presenting with increased comorbidity score is associated with head and neck cancer anatomic subsite. This study aimed at estimating the cumulative odds of increased comorbidity in head and neck cancer based on anatomic subsites. Methods: Data queried

APA, Harvard, Vancouver, ISO, and other styles

21

Li, Daneng, Can-Lan Sun, Abrahm Levi, et al. "Risk factors for hospitalizations (HOS) among older adults with gastrointestinal (GI) cancers receiving chemotherapy." Journal of Clinical Oncology 35, no. 15_suppl (2017): e21523-e21523. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e21523.

Full text

Abstract:

e21523 Background: Older adults undergoing chemotherapy for GI cancers are at increased risk of HOS due to treatment related toxicity; however, there are limited data regarding which individuals are at greatest risk. We therefore sought to identify risk factors for HOS among older adults with GI cancers receiving chemotherapy. Methods: We performed a secondary analysis of patients age ≥ 65 years with GI cancer who participated in either of 2 prospective studies used to develop (n = 500) and validate (n = 250) a geriatric assessment (GA) based chemotherapy toxicity score for older adults with c

APA, Harvard, Vancouver, ISO, and other styles

22

Cawthorpe, David, Marc Kerba, Aru Narendran, Harleen Ghuttora, Gabrielle Chartier, and Norman Sartorius. "Temporal order of cancers and mental disorders in an adult population." BJPsych Open 4, no. 3 (2018): 95–105. http://dx.doi.org/10.1192/bjo.2018.5.

Full text

Abstract:

BackgroundPopulation-based examination of comorbidity is an emerging field of study.AimsThe purpose of the present population level study is to expand our understanding of how cancer and mental illness are temporally associated.MethodA sample of 83 648 056 physician billing records for 664 838 (56% female) unique individuals over the age of 18 was stratified on ages 19–49 years and 50+ years, with temporal order of mental disorder and cancer forming the basis of comparison.ResultsMental disorders preceded cancers for both genders within each age strata. The full range of cancers and mental dis

APA, Harvard, Vancouver, ISO, and other styles

23

Ottesen, Johnny T., and Morten Andersen. "Aging, Inflammation, and Comorbidity in Cancers—A General In Silico Study Exemplified by Myeloproliferative Malignancies." Cancers 15, no. 19 (2023): 4806. http://dx.doi.org/10.3390/cancers15194806.

Full text

Abstract:

(1) Background: We consider dormant, pre-cancerous states prevented from developing into cancer by the immune system. Inflammatory morbidity may compromise the immune system and cause the pre-cancer to escape into an actual cancerous development. The immune deficiency described is general, but the results may vary across specific cancers due to different variances (2) Methods: We formulate a general conceptual model to perform rigorous in silico consequence analysis. Relevant existing data for myeloproliferative malignancies from the literature are used to calibrate the in silico computations.

APA, Harvard, Vancouver, ISO, and other styles

24

Lee, L. M., W. Y. Cheung, and M. K. Krzyzanowska. "A systematic review of the impact of comorbidity on chemotherapy utilization and outcomes in solid tumors." Journal of Clinical Oncology 27, no. 15_suppl (2009): e20646-e20646. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e20646.

Full text

Abstract:

e20646 Background: The management of cancer patients (pts) with comorbidities can be challenging as these individuals are underrepresented in oncology clinical trials. We conducted a systematic literature review to determine the impact of comorbidity on utilization, tolerability, and efficacy of chemotherapy among pts with solid tumors. Methods: Using MEDLINE and EMBASE databases, all English-language articles published from 1990–2008 that explored the association between comorbidity and chemotherapy were identified. MeSH and keyword search terms included “comorbidity,” “chemotherapy” and “can

APA, Harvard, Vancouver, ISO, and other styles

25

Adenekan, Tobiloba Adanma, Julia E. Heck, Cheng Yin, and Johnni Hansen. "Abstract 3441: Application of a maternal comorbidity index to predict childhood cancer risk: A population-based case-control study in Denmark." Cancer Research 84, no. 6_Supplement (2024): 3441. http://dx.doi.org/10.1158/1538-7445.am2024-3441.

Full text

Abstract:

Abstract Background: Maternal health has been found to be an indicator of children’s health and has also been found to affect the risk of childhood diseases. Children are especially susceptible to in-utero exposures. A mother’s health conditions before and during pregnancy could have important consequences for her child's health, including cancer development, as was observed in some prior studies. Objectives: This study aimed to identify the impact of varying maternal comorbidities on the development of childhood cancers. This study applied an Obstetric Comorbidity Index (Bateman et al, 2013)

APA, Harvard, Vancouver, ISO, and other styles

26

Ahmad, Tahania, Abu Z. M. Dayem Ullah, Claude Chelala, and Stephanie J. C. Taylor. "Ethnic and Socio-Economic Variations in Comorbidity and Mortality in Cancer Survivors: A UK Population-Based Observational Study." Cancers 17, no. 6 (2025): 983. https://doi.org/10.3390/cancers17060983.

Full text

Abstract:

The population of cancer survivors is increasing rapidly in the UK. Little is known about the variation in comorbidity and mortality by ethnicity and socio-economic condition in this population. This study explores these variations using primary care data from the Clinical Practice Research Datalink (CPRD) and linked secondary care data. The prevalence of multimorbidity and risk of mortality were calculated for Asian, Black, and Other ethnic and socio-economic groups in England, consisting of 333,226 cancer survivors across 28 cancer types. Odds ratios and hazard ratios were calculated using t

APA, Harvard, Vancouver, ISO, and other styles

27

Chandler, Young, Claudine Isaacs, Jinani Jayasekera, Clyde B. Schechter, Christopher Cadham, and Jeanne S. Mandelblatt. "Using tumor genomic profile testing and comorbidity level to personalize chemotherapy decisions among older patients with early-stage breast cancer." Journal of Clinical Oncology 37, no. 15_suppl (2019): e12055-e12055. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e12055.

Full text

Abstract:

e12055 Background: Under-representation of women ages 65+ (“older”) in the trials may limit clinical translation of results to this growing population. We used simulation modeling to estimate chemotherapy outcomes by age and comorbidity level among older women with early stage, estrogen-receptor+/HER2- breast cancers with an Oncotype DX score of 26+. Methods: A discrete-time stochastic state-transition model synthesized data from population studies and clinical trials to estimate outcomes over a 25-year horizon for subgroups of women based on age (65-69, 70-74, 75-79, and 80-89) and comorbidit

APA, Harvard, Vancouver, ISO, and other styles

28

Lam, Chun Sing, Rong Hua, Herbert Ho-Fung Loong, Chun-Kit Ngan, and Yin Ting Cheung. "Association Between Comorbidity Clusters and Mortality in Patients With Cancer: Predictive Modeling Using Machine Learning Approaches of Data From the United States and Hong Kong." JMIR Cancer 11 (July 16, 2025): e71937-e71937. https://doi.org/10.2196/71937.

Full text

Abstract:

Abstract Background Patients with cancer and cancer survivors often experience multiple chronic health conditions, which can impact symptom burden and treatment outcomes. Despite the high prevalence of multimorbidity, research on cancer prognosis has predominantly focused on cancers in isolation. There is growing interest in machine learning techniques for cancer studies. However, these methods have not been applied in the context of supportive care for patients with cancer who have multimorbidity. Furthermore, few studies have investigated the associations between comorbidity clusters and mor

APA, Harvard, Vancouver, ISO, and other styles

29

Taparra, Kekoa, Vera Qu, and Erqi Pollom. "Disparities in Survival and Comorbidity Burden Between Asian and Native Hawaiian and Other Pacific Islander Patients With Cancer." JAMA Network Open 5, no. 8 (2022): e2226327. http://dx.doi.org/10.1001/jamanetworkopen.2022.26327.

Full text

Abstract:

ImportanceImproper aggregation of Native Hawaiian and other Pacific Islander individuals with Asian individuals can mask Native Hawaiian and other Pacific Islander patient outcomes. A comprehensive assessment of cancer disparities comparing Asian with Native Hawaiian and other Pacific Islander populations is lacking.ObjectiveTo compare comorbidity burden and survival among East Asian, Native Hawaiian and other Pacific Islander, South Asian, and Southeast Asian individuals with non-Hispanic White individuals with cancer.Design, Setting, and ParticipantsThis retrospective cohort study used a nat

APA, Harvard, Vancouver, ISO, and other styles

30

Li, Daneng, Can-Lan Sun, Rebecca Allen, et al. "Risk Factors for Hospitalizations Among Older Adults with Gastrointestinal Cancers." Oncologist 27, no. 1 (2022): e37-e44. http://dx.doi.org/10.1093/oncolo/oyab016.

Full text

Abstract:

Abstract Background Older adults (≥65 years) with gastrointestinal (GI) cancers who receive chemotherapy are at increased risk of hospitalization caused by treatment-related toxicity. Geriatric assessment (GA) has been previously shown to predict risk of toxicity in older adults undergoing chemotherapy. However, studies incorporating the GA specifically in older adults with GI cancers have been limited. This study sought to identify GA-based risk factors for chemotherapy toxicity–related hospitalization among older adults with GI cancers. Patients and Methods We performed a secondary post hoc

APA, Harvard, Vancouver, ISO, and other styles

31

Mu, Xiao-Min, Wei Wang, Fang-Yi Wu, Yu-Ying Jiang, Ling-ling Ma, and Jia Feng. "Comorbidity in Older Patients Hospitalized with Cancer in Northeast China based on Hospital Discharge Data." International Journal of Environmental Research and Public Health 17, no. 21 (2020): 8028. http://dx.doi.org/10.3390/ijerph17218028.

Full text

Abstract:

Patients with cancer often carry the dual burden of the cancer itself and other co-existing medical conditions. The problems associated with comorbidities among elderly cancer patients are more prominent compared with younger patients. This study aimed to identify common cancer-related comorbidities in elderly patients through routinely collected hospital discharge data and to use association rules to analyze the prevalence and patterns of these comorbidities in elderly cancer patients at different cancer sites. We collected the discharge data of 80,574 patients who were diagnosed with cancers

APA, Harvard, Vancouver, ISO, and other styles

32

Pearlstein, Kevin A., Ramsankar Basak, and Ronald C. Chen. "Breast cancer patient functional status and comorbidities and their impact on treatment aggressiveness: A population-based study." Journal of Clinical Oncology 34, no. 7_suppl (2016): 306. http://dx.doi.org/10.1200/jco.2016.34.7_suppl.306.

Full text

Abstract:

306 Background: The ASCO Choosing Wisely Campaign and other published guidelines recommend avoidance of aggressive treatments in early-stage cancer patients with limited life expectancy. However, patients with more advanced cancers are likely to benefit from aggressive treatment. The population-based SEER-MHOS (Medicare Health Outcomes Survey) provides unique data to allow assessment of aggressiveness of cancer treatment by cancer stage and patient frailty. Methods: MHOS includes patient-reported functional deficits in a sample of Medicare beneficiaries, and has been linked with SEER data whic

APA, Harvard, Vancouver, ISO, and other styles

33

Dima, Shinechimeg, Kun-Huang Chen, Kung-Jeng Wang, Kung-Min Wang, and Nai-Chia Teng. "Effect of Comorbidity on Lung Cancer Diagnosis Timing and Mortality: A Nationwide Population-Based Cohort Study in Taiwan." BioMed Research International 2018 (November 4, 2018): 1–9. http://dx.doi.org/10.1155/2018/1252897.

Full text

Abstract:

The effect of comorbidity on lung cancer patients’ survival has been widely reported. The aim of this study was to investigate the effects of comorbidity on the establishment of the diagnosis of lung cancer and survival in lung cancer patients in Taiwan by using a nationwide population-based study design. This study collected various comorbidity patients and analyzed data regarding the lung cancer diagnosis and survival during a 16-year follow-up period (1995–2010). In total, 101,776 lung cancer patients were included, comprising 44,770 with and 57,006 without comorbidity. The Kaplan–Meier ana

APA, Harvard, Vancouver, ISO, and other styles

34

Griffiths, Robert I., Michelle L. Gleeson, José M. Valderas, and Mark D. Danese. "Impact of Undetected Comorbidity on Treatment and Outcomes of Breast Cancer." International Journal of Breast Cancer 2014 (2014): 1–11. http://dx.doi.org/10.1155/2014/970780.

Full text

Abstract:

Preexisting comorbidity adversely impacts breast cancer treatment and outcomes. We examined the incremental impact of comorbidity undetected until cancer. We followed breast cancer patients in SEER-Medicare from 12 months before to 84 months after diagnosis. Two comorbidity indices were constructed: the National Cancer Institute index, using 12 months of claims before cancer, and a second index for previously undetected conditions, using three months after cancer. Conditions present in the first were excluded from the second. Overall, 6,184 (10.1%) had≥1undetected comorbidity. Chronic obstruct

APA, Harvard, Vancouver, ISO, and other styles

35

Salemi, Michele, Maria Paola Mogavero, Giuseppe Lanza, Laura M. Mongioì, Aldo E. Calogero, and Raffaele Ferri. "Examples of Inverse Comorbidity between Cancer and Neurodegenerative Diseases: A Possible Role for Noncoding RNA." Cells 11, no. 12 (2022): 1930. http://dx.doi.org/10.3390/cells11121930.

Full text

Abstract:

Cancer is one of the most common causes of death; in parallel, the incidence and prevalence of central nervous system diseases are equally high. Among neurodegenerative diseases, Alzheimer’s dementia is the most common, while Parkinson’s disease (PD) is the second most frequent neurodegenerative disease. There is a significant amount of evidence on the complex biological connection between cancer and neurodegeneration. Noncoding RNAs (ncRNAs) are defined as transcribed nucleotides that perform a variety of regulatory functions. The mechanisms by which ncRNAs exert their functions are numerous

APA, Harvard, Vancouver, ISO, and other styles

36

Kim, Se-Won, Seok-Jun Yoon, Min-Ho Kyung, Young-Ho Yun, Young-Ae Kim, and Eun-Jung Kim. "Health Outcome Prediction Using the Charlson Comorbidity Index In Lung Cancer Patients." Korean Journal of Health Policy and Administration 19, no. 4 (2009): 18–32. http://dx.doi.org/10.4332/kjhpa.2009.19.4.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Extermann, Martine. "Interaction between Comorbidity and Cancer." Cancer Control 14, no. 1 (2007): 13–22. http://dx.doi.org/10.1177/107327480701400103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Cheng, Feixiong, and Joseph Loscalzo. "Pulmonary Comorbidity in Lung Cancer." Trends in Molecular Medicine 24, no. 3 (2018): 239–41. http://dx.doi.org/10.1016/j.molmed.2018.01.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

López-Encuentra, Angel. "Comorbidity in operable lung cancer." Lung Cancer 35, no. 3 (2002): 263–69. http://dx.doi.org/10.1016/s0169-5002(01)00422-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Thanopoulou, Anastasia, and Demetrios Pectasides. "Real Life Cancer Comorbidity in Greek Patients with Diabetes Mellitus Followed Up at a Single Diabetes Center: An Unappreciated New Diabetes Complication." Journal of Diabetes Research 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/231425.

Full text

Abstract:

We determined cancer comorbidity in patients with diabetes followed up at a single Greek academic clinic and investigated the potential related factors. Cancer comorbidity was prospectively recorded for all patients with type 2 (T2DM,n=759) or type 1 (T1DM,n=134) diabetes of at least 10-year duration examined during one year. Patient characteristics, diabetes age of onset, duration, treatment, control, and complication rates were compared between subjects with and without cancer. Moreover, a retrospective collection of data from similar patients examined for the first time during the last 25 y

APA, Harvard, Vancouver, ISO, and other styles

41

Hines, Robert B., Chakrapani Chatla, Harvey L. Bumpers, et al. "Predictive Capacity of Three Comorbidity Indices in Estimating Mortality After Surgery for Colon Cancer." Journal of Clinical Oncology 27, no. 26 (2009): 4339–45. http://dx.doi.org/10.1200/jco.2009.22.4758.

Full text

Abstract:

Purpose Although, for patients with cancer, comorbidity can affect the timing of cancer detection, treatment, and prognosis, there is little information relating to the question of whether the choice of comorbidity index affects the results of studies. Therefore, to compare the association of comorbidity with mortality after surgery for colon cancer, this study evaluated the Adult Comorbidity Evaluation-27 (ACE-27), the National Institute on Aging (NIA) and National Cancer Institute (NCI) Comorbidity Index, and the Charlson Comorbidity Index (CCI). Patients and Methods The study population con

APA, Harvard, Vancouver, ISO, and other styles

42

Noer, Mette Calundann, Cecilie Dyg Sperling, Bent Ottesen, Sofie Leisby Antonsen, Ib Jarle Christensen, and Claus Høgdall. "Ovarian Cancer and Comorbidity: Is Poor Survival Explained by Choice of Primary Treatment or System Delay?" International Journal of Gynecologic Cancer 27, no. 6 (2017): 1123–33. http://dx.doi.org/10.1097/igc.0000000000001001.

Full text

Abstract:

ObjectivesComorbidity influences survival in ovarian cancer, but the causal relations between prognosis and comorbidity are not well characterized. The aim of this study was to investigate the associations between comorbidity, system delay, the choice of primary treatment, and survival in Danish ovarian cancer patients.MethodsThis population-based study was conducted on data from 5317 ovarian cancer patients registered in the Danish Gynecological Cancer Database. Comorbidity was classified according to the Charlson Comorbidity Index and the Ovarian Cancer Comorbidity Index. Pearson χ2 test and

APA, Harvard, Vancouver, ISO, and other styles

43

Wong, Melisa L., Timothy L. McMurry, Jessica R. Schumacher, et al. "Comorbidity Assessment in the National Cancer Database for Patients With Surgically Resected Breast, Colorectal, or Lung Cancer (AFT-01, -02, -03)." Journal of Oncology Practice 14, no. 10 (2018): e631-e643. http://dx.doi.org/10.1200/jop.18.00175.

Full text

Abstract:

Purpose: Accurate comorbidity measurement is critical for cancer research. We evaluated comorbidity assessment in the National Cancer Database (NCDB), which uses a code-based Charlson-Deyo Comorbidity Index (CCI), and compared its prognostic performance with a chart-based CCI and individual comorbidities in a national sample of patients with breast, colorectal, or lung cancer. Patients and Methods: Through an NCDB Special Study, cancer registrars re-abstracted perioperative comorbidities for 11,243 patients with stage II to III breast cancer, 10,880 with stage I to III colorectal cancer, and 9

APA, Harvard, Vancouver, ISO, and other styles

44

Oguntade, E. S., and D. M. Oladimeji. "Statistical Modelling of Comorbidity Effect on Second Cancer." Nigerian Journal of Basic and Applied Sciences 28, no. 1 (2021): 85–92. http://dx.doi.org/10.4314/njbas.v28i1.11.

Full text

Abstract:

Second cancer is a new cancer that occurs in someone who had history of cancer. The incidence of cancer is on the increase in the global scene and especially in Sub-Saharan Africa. This phenomenon constitutes huge health problems especially with comorbidity effects with other health conditions which have made the diagnosis and treatment of cancer patients a complex issue. Hence, this study determined the comorbidity effect on second cancer based on a retrospective study of 474 patients attending University of Abuja Teaching Hospital (UATH). These patients were first treated of cancer, and afte

APA, Harvard, Vancouver, ISO, and other styles

45

Chang, V. T., N. Sambamoorthi, B. Zhou, et al. "Comorbidity and survival in cancer patients receiving palliative care." Journal of Clinical Oncology 25, no. 18_suppl (2007): 9066. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.9066.

Full text

Abstract:

9066 Background: Comorbidity has received increasing attention in the assessment of patients with early stage cancer, or at diagnosis. We studied whether three indices of comorbidity, the Charlson Comorbidity Index (CMI), the Cumulative Illness Rating Scale (CIRS), and the Kaplan Feinstein Index (KFI) add prognostic information for cancer patients receiving palliative care. Methods: In an IRB approved protocol, 103 patients with advanced cancer were seen at the time they were starting palliative care. They had a Karnofsky Performance Status (KPS) determination, and were followed longitudinally

APA, Harvard, Vancouver, ISO, and other styles

46

Greco, Alessandro, Jon Sanchez Valle, Vera Pancaldi, et al. "Molecular Inverse Comorbidity between Alzheimer’s Disease and Lung Cancer: New Insights from Matrix Factorization." International Journal of Molecular Sciences 20, no. 13 (2019): 3114. http://dx.doi.org/10.3390/ijms20133114.

Full text

Abstract:

Matrix factorization (MF) is an established paradigm for large-scale biological data analysis with tremendous potential in computational biology. Here, we challenge MF in depicting the molecular bases of epidemiologically described disease–disease (DD) relationships. As a use case, we focus on the inverse comorbidity association between Alzheimer’s disease (AD) and lung cancer (LC), described as a lower than expected probability of developing LC in AD patients. To this day, the molecular mechanisms underlying DD relationships remain poorly explained and their better characterization might offe

APA, Harvard, Vancouver, ISO, and other styles

47

Balic, Marija, Wolfgang Hilbe, Sylvia Gusel, et al. "Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria." memo - Magazine of European Medical Oncology 12, no. 4 (2019): 290–96. http://dx.doi.org/10.1007/s12254-019-00542-7.

Full text

Abstract:

Summary The purpose of this observational study was to determine the prevalence of comorbid conditions in cancer patients with solid tumours selected for specific treatment at 12 divisions of medical oncology in Austria. Data from 1137 patients were collected using a standardized questionnaire; of these, 1036 datasets were evaluable for further analysis. Data were prospectively collected from patients during an in- or outpatient hospital visit over a 4-month period in 2011. Of these patients 42% had gastrointestinal cancer, 31% had breast cancer, 9% lung cancer and the remaining had urogenital

APA, Harvard, Vancouver, ISO, and other styles

48

Canoui-Poitrine, Florence, Lauriane Segaux, Marc-Antoine Benderra, et al. "The Prognostic Value of Eight Comorbidity Indices in Older Patients with Cancer: The ELCAPA Cohort Study." Cancers 14, no. 9 (2022): 2236. http://dx.doi.org/10.3390/cancers14092236.

Full text

Abstract:

Background: A prognostic assessment is crucial for making cancer treatment decisions in older patients. We assessed the prognostic performance (relative to one-year mortality) of eight comorbidity indices in a cohort of older patients with cancer. Methods: We studied patients with cancer aged ≥70 included in the Elderly Cancer Patient (ELCAPA) cohort between 2007 and 2010. We assessed seven nonspecific indices (Charlson Comorbidity Index (CCI), three modified versions of the CCI, the Elixhauser Comorbidity Index, the Gagne index, and the Cumulative Illness Rating Scale for Geriatrics (CIRS-G))

APA, Harvard, Vancouver, ISO, and other styles

49

Bragina, Elena Yu, Densema E. Gomboeva, Olga V. Saik, et al. "Apoptosis Genes as a Key to Identification of Inverse Comorbidity of Huntington’s Disease and Cancer." International Journal of Molecular Sciences 24, no. 11 (2023): 9385. http://dx.doi.org/10.3390/ijms24119385.

Full text

Abstract:

Cancer and neurodegenerative disorders present overwhelming challenges for healthcare worldwide. Epidemiological studies showed a decrease in cancer rates in patients with neurodegenerative disorders, including the Huntington disease (HD). Apoptosis is one of the most important processes for both cancer and neurodegeneration. We suggest that genes closely connected with apoptosis and associated with HD may affect carcinogenesis. We applied reconstruction and analysis of gene networks associated with HD and apoptosis and identified potentially important genes for inverse comorbidity of cancer a

APA, Harvard, Vancouver, ISO, and other styles

50

Abouelella, Dina K., Alexandra Belcastro, Shreya P. Ramkumar, et al. "Abstract C010: Racial and ethnic differences in stage of presentation, comorbidity burden, and overall survival of oral cavity cancer." Cancer Epidemiology, Biomarkers & Prevention 32, no. 12_Supplement (2023): C010. http://dx.doi.org/10.1158/1538-7755.disp23-c010.

Full text

Abstract:

Abstract Background: Oral squamous cell carcinoma (OSCC) is one of the most common head and neck cancer subsites. Head and neck cancer (HNC) has the third worst Black vs. White five-year survival rate of all cancers in the United States. Among the most important determinants of survival in OSCC and HNC in general are clinical factors such as stage of disease presentation and patients' comorbidity burden. It is unclear, however, how these prognostic clinical factors differ based on sex, or race and ethnicity. This study aimed to examine racial/ethnic and sex differences in stage of presentation

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!